<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Hospital and Severance Cardiovascular Hospital and Integrated Research Center for" exact="Cerebrovascular" post="and Cardiovascular diseases, Yonsei University College of Medicine, [2],"/>
 <result pre="world and it is predominantly used in the elderly subjects." exact="Pneumonia" post="is the most common cause of death in the"/>
 <result pre="common cause of death in the extremely old subject. During" exact="infection" post="and its complication such as sepsis, hypotension could be"/>
 <result pre="sympathetic nervous system can be mitigated by antihypertensive drug therapy." exact="Severe" post="Acute Respiratory Syndrome-Coronavirus-1 and 2 viral surface protein is"/>
 <result pre="nervous system can be mitigated by antihypertensive drug therapy. Severe" exact="Acute" post="Respiratory Syndrome-Coronavirus-1 and 2 viral surface protein is known"/>
 <result pre="system can be mitigated by antihypertensive drug therapy. Severe Acute" exact="Respiratory" post="Syndrome-Coronavirus-1 and 2 viral surface protein is known to"/>
 <result pre="by antihypertensive drug therapy. Severe Acute Respiratory Syndrome-Coronavirus-1 and 2" exact="viral" post="surface protein is known to attach angiotensin converting enzyme"/>
 <result pre="converting enzyme 2 (ACE2) on the cell membrane to facilitate" exact="viral" post="entry into the cytoplasm. Despite the theoretical concerns of"/>
 <result pre="is no evidence that RAS inhibitors are harmful during COVID-19" exact="infection" post="and have in fact been shown to be beneficial"/>
 <result pre="maintain RAS blockade during the current corona virus pandemic. Keywords" exact="Hypertension" post="Infection SARS COVID-19 2019 novel coronavirus SARS-CoV-2 Sepsis Pandemic"/>
 <result pre="RAS blockade during the current corona virus pandemic. Keywords Hypertension" exact="Infection" post="SARS COVID-19 2019 novel coronavirus SARS-CoV-2 Sepsis Pandemic Antihypertensive"/>
 <result pre="blocker ACE2 Background In the era of extremely aging society," exact="hypertension" post="is a highly prevalent chronic condition in the elderly"/>
 <result pre="era of extremely aging society, hypertension is a highly prevalent" exact="chronic" post="condition in the elderly that will overlap with many"/>
 <result pre="chronic condition in the elderly that will overlap with many" exact="acute" post="conditions such as infection, surgery, trauma or intoxication. Infection"/>
 <result pre="many acute conditions such as infection, surgery, trauma or intoxication." exact="Infection" post="is an unavoidable clinical problem in the elderly patient"/>
 <result pre="unavoidable clinical problem in the elderly patient taking antihypertensive medications." exact="Pneumonia" post="and influenza could be fatal in the elderly patients"/>
 <result pre="and influenza could be fatal in the elderly patients with" exact="cardiovascular" post="complications, which are the result of long-term hypertension and"/>
 <result pre="patients with cardiovascular complications, which are the result of long-term" exact="hypertension" post="and other risk factors. In fact, vaccination against pneumonia"/>
 <result pre="long-term hypertension and other risk factors. In fact, vaccination against" exact="pneumonia" post="and influenza is highly recommended in elderly with or"/>
 <result pre="and influenza is highly recommended in elderly with or without" exact="cardiovascular" post="complications. Recent pandemic outbreak of Severe Acute Respiratory Syndrome"/>
 <result pre="elderly with or without cardiovascular complications. Recent pandemic outbreak of" exact="Severe" post="Acute Respiratory Syndrome corona virus 2 (SARS-CoV-2), so called,"/>
 <result pre="with or without cardiovascular complications. Recent pandemic outbreak of Severe" exact="Acute" post="Respiratory Syndrome corona virus 2 (SARS-CoV-2), so called, coronavirus"/>
 <result pre="or without cardiovascular complications. Recent pandemic outbreak of Severe Acute" exact="Respiratory" post="Syndrome corona virus 2 (SARS-CoV-2), so called, coronavirus disease"/>
 <result pre="without cardiovascular complications. Recent pandemic outbreak of Severe Acute Respiratory" exact="Syndrome" post="corona virus 2 (SARS-CoV-2), so called, coronavirus disease 2019"/>
 <result pre="Acute Respiratory Syndrome corona virus 2 (SARS-CoV-2), so called, coronavirus" exact="disease" post="2019 (COVID-19) are posing a similar challenge in which"/>
 <result pre="of fatalities are being observed in the elderly with hypertension," exact="diabetes" post="and/or their complications. Antihypertensive drug therapy may have an"/>
 <result pre="volume depletion, orthostatic hypotension to severe conditions such as sepsis," exact="septic shock," post="myocardial damage, overt hear failure, acute kidney injury, and/or"/>
 <result pre="such as sepsis, septic shock, myocardial damage, overt hear failure," exact="acute" post="kidney injury, and/or multiple organ failure. The changes in"/>
 <result pre="as sepsis, septic shock, myocardial damage, overt hear failure, acute" exact="kidney injury," post="and/or multiple organ failure. The changes in antihypertensive drug"/>
 <result pre="of antihypertensive drugs in terms of vulnerability to specific infection," exact="septic shock," post="and/or organ failure. General aspects of infection and hypertension"/>
 <result pre="of vulnerability to specific infection, septic shock, and/or organ failure." exact="General" post="aspects of infection and hypertension management There are some"/>
 <result pre="specific infection, septic shock, and/or organ failure. General aspects of" exact="infection" post="and hypertension management There are some general aspects in"/>
 <result pre="septic shock, and/or organ failure. General aspects of infection and" exact="hypertension" post="management There are some general aspects in relation to"/>
 <result pre="hypertension management There are some general aspects in relation to" exact="hypertension" post="management or antihypertensive drug use when some infection is"/>
 <result pre="relation to hypertension management or antihypertensive drug use when some" exact="infection" post="is impending or ongoing. First of all, because hypertension"/>
 <result pre="some infection is impending or ongoing. First of all, because" exact="hypertension" post="is basically dependent on the sodium balance, when sodium"/>
 <result pre="blockade or beta blocker is recommended for the patient with" exact="cardiovascular" post="complications, stopping these drugs may be harmful. In a"/>
 <result pre="modulation can be a signal for sepsis in patient with" exact="infection" post="[2]. Some mediators to suppress sympathetic nervous system may"/>
 <result pre="to already established sympathetic blockade. Similarly, in retrospective studies for" exact="heart" post="failure patients, withdrawal of RAS blockade or beta blocker"/>
 <result pre="there is no evidence to stop using these drugs in" exact="infection" post="patients unless they are associated with hemodynamic instability. However,"/>
 <result pre="with hemodynamic instability. However, in patients with volume depletion and" exact="symptomatic" post="hypotension, it would be prudent to stop antihypertensive medications"/>
 <result pre="seems to be possible only when the patient has no" exact="hypertension" post="related complications such as heart failure, coronary artery disease,"/>
 <result pre="when the patient has no hypertension related complications such as" exact="heart" post="failure, coronary artery disease, and other vascular complications. Even"/>
 <result pre="patient has no hypertension related complications such as heart failure," exact="coronary artery disease," post="and other vascular complications. Even in these subjects, one"/>
 <result pre="has no hypertension related complications such as heart failure, coronary" exact="artery disease," post="and other vascular complications. Even in these subjects, one"/>
 <result pre="complications such as heart failure, coronary artery disease, and other" exact="vascular" post="complications. Even in these subjects, one should consider the"/>
 <result pre="Ohkubo et al., including 6105 patients with a history of" exact="stroke" post="and/or transient ischemic attack (mean age, 64â€‰years), it was"/>
 <result pre="al., including 6105 patients with a history of stroke and/or" exact="transient ischemic attack" post="(mean age, 64â€‰years), it was reported that perindopril decreased"/>
 <result pre="attack (mean age, 64â€‰years), it was reported that perindopril decreased" exact="pneumonia" post="risk in Asian but not in non-Asian subjects [5]."/>
 <result pre="in a real world clinical practice for the patient with" exact="acute" post="hypotension, acute kidney injury, or hyperkalemia related to infection"/>
 <result pre="real world clinical practice for the patient with acute hypotension," exact="acute" post="kidney injury, or hyperkalemia related to infection [6]. Besides"/>
 <result pre="world clinical practice for the patient with acute hypotension, acute" exact="kidney injury," post="or hyperkalemia related to infection [6]. Besides the toxin"/>
 <result pre="with acute hypotension, acute kidney injury, or hyperkalemia related to" exact="infection" post="[6]. Besides the toxin supplied by infectious organisms, catecholamine"/>
 <result pre="hyperkalemia related to infection [6]. Besides the toxin supplied by" exact="infectious" post="organisms, catecholamine or stress induced cardiomyopathy, tachycardia induced cardiomyopathy,"/>
 <result pre="stress induced cardiomyopathy, tachycardia induced cardiomyopathy, and direct invasion of" exact="infectious" post="agents could precipitate hypotension during infection. Acute hemodynamic instability"/>
 <result pre="direct invasion of infectious agents could precipitate hypotension during infection." exact="Acute" post="hemodynamic instability or hypotension is a serious condition during"/>
 <result pre="Acute hemodynamic instability or hypotension is a serious condition during" exact="acute" post="infection which requires stopping or adjustment of antihypertensive drug"/>
 <result pre="hemodynamic instability or hypotension is a serious condition during acute" exact="infection" post="which requires stopping or adjustment of antihypertensive drug dosage"/>
 <result pre="antihypertensive drug dosage according to the patientâ€™s hemodynamic status. Pandemic" exact="viral" post="diseases Yearly outbreak of the seasonal flu is a"/>
 <result pre="patients with high risk profiles such as older age, diabetes," exact="chronic" post="diseases of the heart, kidney, lung, and liver [7]."/>
 <result pre="strategies to cope with it, which are specific to the" exact="infectious" post="agent such as anti-viral therapy, vaccination, and other preventive"/>
 <result pre="agent such as anti-viral therapy, vaccination, and other preventive approaches." exact="Hypertension" post="is prevalent in high risk flu patients because they"/>
 <result pre="risk flu patients because they are usually older and with" exact="cardiovascular" post="complications. But antihypertensive agents could be adjusted according to"/>
 <result pre="adjusted according to the general and hemodynamic conditions only after" exact="infection" post="begins and it will be only temporary even when"/>
 <result pre="issue about adjustment of antihypertensive drug use to protect from" exact="infection" post="preemptively because there is no direct involvement of antihypertensive"/>
 <result pre="there is no direct involvement of antihypertensive drugs in the" exact="infectious" post="process itself. In contrast to pandemic flu, it is"/>
 <result pre="highlighted that angiotensin converting enzyme 2 (ACE2) of the lung" exact="type 2" post="alveolar epithelial cell acts as a non-catalytic receptor for"/>
 <result pre="converting enzyme 2 (ACE2) of the lung type 2 alveolar" exact="epithelial" post="cell acts as a non-catalytic receptor for SARS-CoV-1 and"/>
 <result pre="infect the cell [8]. ACE2 is reported to be predominantly" exact="localized" post="on endothelial cells. Its mRNA is reported to be"/>
 <result pre="reported to be most highly expressed in testis, kidney, and," exact="heart" post="and also expressed in brain, intestine, and lungs [9]."/>
 <result pre="and lungs [9]. Thus, there have been growing concerns about" exact="hypertension" post="being a risk factor for severe COVID-19 and the"/>
 <result pre="COVID-19 due to the theoretical increase in the expression of" exact="systemic" post="ACE2 with its use. The pandemic of SARS-CoV-2 which"/>
 <result pre="China from December 2019, has spread rapidly around the world." exact="Severe" post="lung damage and high mortality rates have been reported,"/>
 <result pre="and those with comorbidities. In particular, the high prevalence of" exact="hypertension" post="and diabetes suggests that they maybe risk factors for"/>
 <result pre="with comorbidities. In particular, the high prevalence of hypertension and" exact="diabetes" post="suggests that they maybe risk factors for severe COVID-19."/>
 <result pre="they maybe risk factors for severe COVID-19. The prevalence of" exact="hypertension" post="is apparently high in patients with severe COVID-19, however,"/>
 <result pre="considering the age of those patients, the actual prevalence of" exact="hypertension" post="does not seem to be higher. Zhou et al."/>
 <result pre="age of deaths (nâ€‰=â€‰54) was 69â€‰years, and the prevalence of" exact="hypertension" post="was 48%, which is quite comparable to the prevalence"/>
 <result pre="was 48%, which is quite comparable to the prevalence of" exact="hypertension" post="in the representative population of those ages [10]. Until"/>
 <result pre="none of the papers published through multivariate analysis indicated that" exact="hypertension" post="was an independent risk factor for severe COVID-19. In"/>
 <result pre="of 1099 COVID-19 patients diagnosed in Wuhan, the prevalence of" exact="hypertension" post="was higher in severe patients (Nâ€‰=â€‰173, mean age 52â€‰years)"/>
 <result pre="it was not particularly higher when considering the prevalence of" exact="hypertension" post="in that age group [11]. Therefore, there is no"/>
 <result pre="[11]. Therefore, there is no scientific evidence to suggest that" exact="hypertension" post="itself is an independent risk factor for severe infection"/>
 <result pre="that hypertension itself is an independent risk factor for severe" exact="infection" post="or mortality by COVID-19. The higher prevalence of hypertension"/>
 <result pre="severe infection or mortality by COVID-19. The higher prevalence of" exact="hypertension" post="in patients with COVID-19 is more likely due to"/>
 <result pre="severe patients was significantly older and because major complications of" exact="hypertension" post="such as chronic heart failure, cerebral infarction, and chronic"/>
 <result pre="significantly older and because major complications of hypertension such as" exact="chronic" post="heart failure, cerebral infarction, and chronic renal failure make"/>
 <result pre="older and because major complications of hypertension such as chronic" exact="heart" post="failure, cerebral infarction, and chronic renal failure make the"/>
 <result pre="because major complications of hypertension such as chronic heart failure," exact="cerebral" post="infarction, and chronic renal failure make the patient much"/>
 <result pre="of hypertension such as chronic heart failure, cerebral infarction, and" exact="chronic" post="renal failure make the patient much more vulnerable to"/>
 <result pre="hypertension such as chronic heart failure, cerebral infarction, and chronic" exact="renal failure" post="make the patient much more vulnerable to progression to"/>
 <result pre="make the patient much more vulnerable to progression to severe" exact="infection" post="or death. In 2004, since the SARS-CoV-1 outbreak in"/>
 <result pre="coronavirus has been shown to use ACE2 proteins in the" exact="epithelial" post="cell membrane in the lung alveoli as a receptor."/>
 <result pre="cell membrane in the lung alveoli as a receptor. The" exact="viral" post="spike(S) glycoprotein attaches to the ACE2 proteins which have"/>
 <result pre="to the ACE2 proteins which have been shown to facilitate" exact="viral" post="entry and in theory, make the patient vulnerable to"/>
 <result pre="viral entry and in theory, make the patient vulnerable to" exact="lower" post="respiratory tract infection or viral pneumonia [12, 13]. Since"/>
 <result pre="entry and in theory, make the patient vulnerable to lower" exact="respiratory" post="tract infection or viral pneumonia [12, 13]. Since the"/>
 <result pre="in theory, make the patient vulnerable to lower respiratory tract" exact="infection" post="or viral pneumonia [12, 13]. Since the COVID-19 outbreak,"/>
 <result pre="make the patient vulnerable to lower respiratory tract infection or" exact="viral pneumonia" post="[12, 13]. Since the COVID-19 outbreak, role of ACE2"/>
 <result pre="the patient vulnerable to lower respiratory tract infection or viral" exact="pneumonia" post="[12, 13]. Since the COVID-19 outbreak, role of ACE2"/>
 <result pre="Angiotensin 1â€&quot;7 is known to have an effect of protecting" exact="cardiovascular" post="diseases by binding to the receptor Mas receptor to"/>
 <result pre="increased risk of severe COVID-19. However, the Korean society of" exact="Hypertension" post="would like to emphasize that currently, there is no"/>
 <result pre="not RAS inhibition results in increased expression of ACE2 in" exact="systemic" post="level and/or tissue including epithelial cells (Fig. 1). Even"/>
 <result pre="increased expression of ACE2 in systemic level and/or tissue including" exact="epithelial" post="cells (Fig. 1). Even though there are reports that"/>
 <result pre="SARS-CoV-1 and 2, if RAS blockade does indeed exacerbates corona" exact="virus infection," post="obvious increase in mortality and severe infection in patients"/>
 <result pre="exacerbates corona virus infection, obvious increase in mortality and severe" exact="infection" post="in patients receiving RAS inhibitor should have been reported"/>
 <result pre="contrary, it has been reported that ACE2 protects against severe" exact="acute" post="lung injury. Study by Deshotels et al. have shown"/>
 <result pre="in vivo studies have shown that decreased ACE2 during SARS-CoV-1" exact="infection" post="exacerbated acute lung injury. Imai et al. conducted experiments"/>
 <result pre="studies have shown that decreased ACE2 during SARS-CoV-1 infection exacerbated" exact="acute" post="lung injury. Imai et al. conducted experiments by inducing"/>
 <result pre="acute lung injury. Imai et al. conducted experiments by inducing" exact="acute" post="lung injury through gastric acid aspiration in mice. In"/>
 <result pre="through gastric acid aspiration in mice. In ACE knockout mice," exact="acute" post="lung injury was significantly inhibited, whereas in ACE2 knockout"/>
 <result pre="lung injury was significantly inhibited, whereas in ACE2 knockout mice," exact="acute" post="lung injury worsened compared to wild type. On the"/>
 <result pre="injury worsened compared to wild type. On the other hand," exact="acute" post="lung injury was significantly improved by recombinant ACE2 administration,"/>
 <result pre="recombinant ACE2 administration, demonstrating the protective effect of ACE2 in" exact="acute" post="lung injury [20]. In addition, Kuba et al. conducted"/>
 <result pre="ACE2 and downregulates ACE2 and activates Angiotensin II to exacerbate" exact="acute" post="lung injury. In contrast, RAS blockade with losartan 15â€‰mg/kg"/>
 <result pre="RAS blockade with losartan 15â€‰mg/kg had a protective effect against" exact="acute" post="lung injury caused by SARS-CoV-1 infection (Fig 1, b)."/>
 <result pre="a protective effect against acute lung injury caused by SARS-CoV-1" exact="infection" post="(Fig 1, b). Given that COVID-19 has similar pathophysiological"/>
 <result pre="ACE2 or RAS blockade might even be protective against severe" exact="infection" post="or death. Fig. 1 Angiotensin Converting Enzyme 2 in"/>
 <result pre="and II to Angiotensin 1â€&quot;9 and 1â€&quot;7, respectively. Panel b." exact="Complex" post="interaction among SARS-CoV-1, ACE2, TMPRSS2, and ADAM17 in lung"/>
 <result pre="Complex interaction among SARS-CoV-1, ACE2, TMPRSS2, and ADAM17 in lung" exact="epithelial" post="cells. In SARS-CoV-1 infection and presumably in SARS-CoV-2 infection,"/>
 <result pre="ACE2, TMPRSS2, and ADAM17 in lung epithelial cells. In SARS-CoV-1" exact="infection" post="and presumably in SARS-CoV-2 infection, binding of spike protein"/>
 <result pre="mediated ACE2 shedding from cell membrane resulting in promotion of" exact="viral" post="entry, facilitation of ACE2 mediated viral entry by TMPRSS2"/>
 <result pre="resulting in promotion of viral entry, facilitation of ACE2 mediated" exact="viral" post="entry by TMPRSS2 make a complex expression or interplay"/>
 <result pre="17; ARB; angiotensin receptor blocker; S, spike protein; SARS-CoV, severe" exact="acute" post="respiratory syndrome corona virus; TMPRSS2, The type II transmembrane"/>
 <result pre="ARB; angiotensin receptor blocker; S, spike protein; SARS-CoV, severe acute" exact="respiratory" post="syndrome corona virus; TMPRSS2, The type II transmembrane serine"/>
 <result pre="angiotensin receptor blocker; S, spike protein; SARS-CoV, severe acute respiratory" exact="syndrome" post="corona virus; TMPRSS2, The type II transmembrane serine proteases"/>
 <result pre="protein; SARS-CoV, severe acute respiratory syndrome corona virus; TMPRSS2, The" exact="type II" post="transmembrane serine proteases In summary, 1) the prevalence of"/>
 <result pre="II transmembrane serine proteases In summary, 1) the prevalence of" exact="hypertension" post="in patients with severe COVID-19 is high. However, it"/>
 <result pre="be older and commonly have complications of hypertension, such as" exact="heart" post="failure, coronary artery disease, stroke and CKD. Currently, there"/>
 <result pre="and commonly have complications of hypertension, such as heart failure," exact="coronary artery disease," post="stroke and CKD. Currently, there is no scientific evidence"/>
 <result pre="commonly have complications of hypertension, such as heart failure, coronary" exact="artery disease," post="stroke and CKD. Currently, there is no scientific evidence"/>
 <result pre="complications of hypertension, such as heart failure, coronary artery disease," exact="stroke" post="and CKD. Currently, there is no scientific evidence that"/>
 <result pre="stroke and CKD. Currently, there is no scientific evidence that" exact="hypertension" post="is an independent risk factor for severe infection or"/>
 <result pre="evidence that hypertension is an independent risk factor for severe" exact="infection" post="or death until proven otherwise. 2) Regarding the concerns"/>
 <result pre="otherwise. 2) Regarding the concerns for increased risk of severe" exact="infection" post="or death due to the theoretical concerns that taking"/>
 <result pre="of SARS-CoV-1 infection. 3) If RAS inhibitors administered due to" exact="high blood pressure" post="or other cardiovascular disease were stopped abruptly, there is"/>
 <result pre="RAS inhibitors administered due to high blood pressure or other" exact="cardiovascular disease" post="were stopped abruptly, there is risk for excessive increase"/>
 <result pre="inhibitors administered due to high blood pressure or other cardiovascular" exact="disease" post="were stopped abruptly, there is risk for excessive increase"/>
 <result pre="risk for excessive increase in blood pressure that may precipitate" exact="cardiovascular" post="complications. However, we do acknowledge that the above-mentioned issues"/>
 <result pre="scientific evidence to suggest otherwise, we the Korean Society of" exact="Hypertension" post="endorse the recent recommendation by the European Society of"/>
 <result pre="the European Society of Cardiology and recommend 1) In hemodynamically" exact="stable" post="patients who were taking RAS inhibitors to be maintained"/>
 <result pre="conclusion, the use or temporary adjustment of antihypertension drugs during" exact="infectious disease" post="could be individualized according to volume status, hemodynamic stability,"/>
 <result pre="the use or temporary adjustment of antihypertension drugs during infectious" exact="disease" post="could be individualized according to volume status, hemodynamic stability,"/>
 <result pre="could be individualized according to volume status, hemodynamic stability, comorbid" exact="cardiovascular disease" post="profiles, and antihypertensive drug class. Also, the use of"/>
 <result pre="be individualized according to volume status, hemodynamic stability, comorbid cardiovascular" exact="disease" post="profiles, and antihypertensive drug class. Also, the use of"/>
 <result pre="class. Also, the use of RAS blockade SARS-CoV-2 pandemic before" exact="infection" post="should be maintained based on the current scientific knowledge."/>
 <result pre="for the use of antihypertensive drugs before and during severe" exact="infection" post="or epidemics. Publisherâ€™s Note Springer Nature remains neutral with"/>
 <result pre="published by the executive board members of Korean Society of" exact="Hypertension" post="(KSH). They are representing the KSH. Authorsâ€™ contributions S"/>
 <result pre="enzyme inhibitors/angiotensin receptor blockers and outcomes in patients hospitalized with" exact="heart" post="failure with reduced ejection fraction. J Am Heart Assoc."/>
 <result pre="hospitalized with heart failure with reduced ejection fraction. J Am" exact="Heart" post="Assoc. 2017;6. 4.PrinsKWNeillJMTylerJOEckmanPMDuvalSEffects of Beta-blocker withdrawal in acute decompensated"/>
 <result pre="J Am Heart Assoc. 2017;6. 4.PrinsKWNeillJMTylerJOEckmanPMDuvalSEffects of Beta-blocker withdrawal in" exact="acute" post="decompensated heart failure: a systematic review and meta-analysisJACC Heart"/>
 <result pre="Heart Assoc. 2017;6. 4.PrinsKWNeillJMTylerJOEckmanPMDuvalSEffects of Beta-blocker withdrawal in acute decompensated" exact="heart" post="failure: a systematic review and meta-analysisJACC Heart Fail2015364765310.1016/j.jchf.2015.03.00826251094 5.OhkuboTChapmanNNealBWoodwardMOmaeTChalmersJet"/>
 <result pre="in acute decompensated heart failure: a systematic review and meta-analysisJACC" exact="Heart" post="Fail2015364765310.1016/j.jchf.2015.03.00826251094 5.OhkuboTChapmanNNealBWoodwardMOmaeTChalmersJet al.Effects of an angiotensin-converting enzyme inhibitor-based regimen"/>
 <result pre="Fail2015364765310.1016/j.jchf.2015.03.00826251094 5.OhkuboTChapmanNNealBWoodwardMOmaeTChalmersJet al.Effects of an angiotensin-converting enzyme inhibitor-based regimen on" exact="pneumonia" post="riskAm J Respir Crit Care Med20041691041104510.1164/rccm.200309-1219OC14990394 6.LeeJHKimMSYooBSParkSJParkJJShinMSet al.KSHF guidelines"/>
 <result pre="Crit Care Med20041691041104510.1164/rccm.200309-1219OC14990394 6.LeeJHKimMSYooBSParkSJParkJJShinMSet al.KSHF guidelines for the Management of" exact="Acute" post="Heart Failure: part II. Treatment of Acute Heart FailureKorean"/>
 <result pre="Care Med20041691041104510.1164/rccm.200309-1219OC14990394 6.LeeJHKimMSYooBSParkSJParkJJShinMSet al.KSHF guidelines for the Management of Acute" exact="Heart" post="Failure: part II. Treatment of Acute Heart FailureKorean Circ"/>
 <result pre="the Management of Acute Heart Failure: part II. Treatment of" exact="Acute" post="Heart FailureKorean Circ J201949224510.4070/kcj.2018.034930637994 7.British Infection S, British Thoracic"/>
 <result pre="Management of Acute Heart Failure: part II. Treatment of Acute" exact="Heart" post="FailureKorean Circ J201949224510.4070/kcj.2018.034930637994 7.British Infection S, British Thoracic S,"/>
 <result pre="part II. Treatment of Acute Heart FailureKorean Circ J201949224510.4070/kcj.2018.034930637994 7.British" exact="Infection" post="S, British Thoracic S, Health Protection A. Pandemic flu:"/>
 <result pre="of Acute Heart FailureKorean Circ J201949224510.4070/kcj.2018.034930637994 7.British Infection S, British" exact="Thoracic" post="S, Health Protection A. Pandemic flu: clinical management of"/>
 <result pre="illness during an influenza pandemic. Provisional guidelines from the British" exact="Infection" post="Society, British Thoracic Society, and Health Protection Agency in"/>
 <result pre="influenza pandemic. Provisional guidelines from the British Infection Society, British" exact="Thoracic" post="Society, and Health Protection Agency in collaboration with the"/>
 <result pre="therapeutic approaches targeting the renin-angiotensin system and associated peptides in" exact="hypertension" post="and heart failurePharmacol Rev20197153957010.1124/pr.118.01712931537750 9.TipnisSRHooperNMHydeRKarranEChristieGTurnerAJA human homolog of angiotensin-converting"/>
 <result pre="approaches targeting the renin-angiotensin system and associated peptides in hypertension" exact="and heart" post="failurePharmacol Rev20197153957010.1124/pr.118.01712931537750 9.TipnisSRHooperNMHydeRKarranEChristieGTurnerAJA human homolog of angiotensin-converting enzyme. Cloning"/>
 <result pre="targeting the renin-angiotensin system and associated peptides in hypertension and" exact="heart" post="failurePharmacol Rev20197153957010.1124/pr.118.01712931537750 9.TipnisSRHooperNMHydeRKarranEChristieGTurnerAJA human homolog of angiotensin-converting enzyme. Cloning"/>
 <result pre="et al. Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="Ou CQ, He JX, et al. Clinical characteristics of coronavirus" exact="disease" post="2019 in China. N Engl J Med. 2020. 12.HammingITimensWBulthuisMLLelyATNavisGvan"/>
 <result pre="improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental" exact="acute" post="respiratory distress syndromeIntensive Care Med Exp201534410.1186/s40635-015-0044-326215809 16.BurrellLMRisvanisJKubotaEDeanRGMacDonaldPSLuSet al.Myocardial infarction"/>
 <result pre="oxygenation, while reducing cellular infiltrate and fibrosis in experimental acute" exact="respiratory" post="distress syndromeIntensive Care Med Exp201534410.1186/s40635-015-0044-326215809 16.BurrellLMRisvanisJKubotaEDeanRGMacDonaldPSLuSet al.Myocardial infarction increases"/>
 <result pre="16.BurrellLMRisvanisJKubotaEDeanRGMacDonaldPSLuSet al.Myocardial infarction increases ACE2 expression in rat and humansEur" exact="Heart" post="J20052636937510.1093/eurheartj/ehi11415671045 17.WaltersTEKalmanJMPatelSKMearnsMVelkoskaEBurrellLMAngiotensin converting enzyme 2 activity and human atrial"/>
 <result pre="increased plasma angiotensin converting enzyme 2 activity is associated with" exact="atrial fibrillation" post="and more advanced left atrial structural remodellingEuropace2017191280128727738071 18.DeshotelsMRXiaHSriramulaSLazartiguesEFilipeanuCMAngiotensin II"/>
 <result pre="plasma angiotensin converting enzyme 2 activity is associated with atrial" exact="fibrillation" post="and more advanced left atrial structural remodellingEuropace2017191280128727738071 18.DeshotelsMRXiaHSriramulaSLazartiguesEFilipeanuCMAngiotensin II"/>
 <result pre="left atrial structural remodellingEuropace2017191280128727738071 18.DeshotelsMRXiaHSriramulaSLazartiguesEFilipeanuCMAngiotensin II mediates angiotensin converting enzyme" exact="type 2" post="internalization and degradation through an angiotensin II type I"/>
 <result pre="enzyme type 2 internalization and degradation through an angiotensin II" exact="type I" post="receptor-dependent mechanismHypertension2014641368137510.1161/HYPERTENSIONAHA.114.0374325225202 19.HeurichAHofmann-WinklerHGiererSLiepoldTJahnOPohlmannSTMPRSS2 and ADAM17 cleave ACE2 differentially and"/>
 <result pre="only proteolysis by TMPRSS2 augments entry driven by the severe" exact="acute" post="respiratory syndrome coronavirus spike proteinJ Virol2014881293130710.1128/JVI.02202-1324227843 20.ImaiYKubaKRaoSHuanYGuoFGuanBet al.Angiotensin-converting enzyme"/>
 <result pre="proteolysis by TMPRSS2 augments entry driven by the severe acute" exact="respiratory" post="syndrome coronavirus spike proteinJ Virol2014881293130710.1128/JVI.02202-1324227843 20.ImaiYKubaKRaoSHuanYGuoFGuanBet al.Angiotensin-converting enzyme 2"/>
 <result pre="by TMPRSS2 augments entry driven by the severe acute respiratory" exact="syndrome" post="coronavirus spike proteinJ Virol2014881293130710.1128/JVI.02202-1324227843 20.ImaiYKubaKRaoSHuanYGuoFGuanBet al.Angiotensin-converting enzyme 2 protects"/>
 <result pre="spike proteinJ Virol2014881293130710.1128/JVI.02202-1324227843 20.ImaiYKubaKRaoSHuanYGuoFGuanBet al.Angiotensin-converting enzyme 2 protects from severe" exact="acute" post="lung failureNature200543611211610.1038/nature0371216001071"/>
</results>
